Image

About Our Products and Services

Your Trusted Partner

Foundation Medicine has the most experience with comprehensive genomic profiling in the industry.* By partnering with biopharma and clinical stakeholders alike, we’ve developed an extensive genomic database and body of research that have strengthened the services we can offer all of our customers.

Our CGP Portfolio

Image
FPO_05_Single_OH__F1_CDx.png

FoundationOne®CDx

FDA-approved tissue-based broad companion diagnostic for all solid tumors, indicated for 20+ targeted therapies.

LEARN MORE ABOUT FOUNDATIONONE CDX

Image
FPO_04_Single_OH__F1_LCDx.png

FoundationOne®Liquid CDx

FDA-approved blood-based companion diagnostic for all solid tumors, indicated for 8 targeted therapies.

LEARN MORE ABOUT FOUNDATIONONE LIQUID CDX

Image
FoundationOne Heme Close-Up

FoundationOne®Heme

A laboratory developed test for hematologic malignancies, sarcomas or solid tumors where known or novel gene fusion detection is desired.

LEARN MORE ABOUT FOUNDATIONONE HEME

Our Monitoring Solutions

Image

FoundationOne Tracker ctDNA monitoring

Our new tissue-informed ctDNA monitoring test, FoundationOne®Tracker, provides objective insights to help you understand treatment response for patients with advanced cancer across all solid tumors.

Image

Our proven portfolio of tests and services brings in-depth genomic insights, experience, and a breadth of offerings into each practice we work with.

Image

We provide actionable insights into the genomics of both rare and common cancers, fueling discovery through commercialization by using a robust database and having deep experience with FDA approvals.

Foundation Facts & Figures

Over 1 Million

FOUNDATION MEDICINE REPORTS DELIVERED

500+

PEER-REVIEWED PUBLICATIONS

60%

OF ALL US CDX APPROVALS FOR NGS TESTING*

Recent Updates

Image

Actionable Insights Upfront

We understand that treatment planning for your cancer patients can be complex. That’s why we’re updating our FoundationOne CDx and FoundationOne Liquid CDx reports to pull the “Professional Services” summary section to the first page. This update will bring information for all reported biomarker and genomic findings and our new “Report Highlights” section upfront, to help you focus on the critical findings for your patients.

Image
FPO_05_Single_OH__F1_CDx.png

FoundationOne®CDx Adds First Group-Based CDx Claim

The U.S. Food and Drug Administration (FDA) has approved FoundationOne CDx as a companion diagnostic for a group of BRAF inhibitors and BRAF/MEK inhibitors in combination for melanoma patients with BRAF V600E and BRAF V600E/K mutations. FoundationOne CDx is the first comprehensive genomic profiling test to receive approval for a group-based companion diagnostic (CDx) claim.1 Based on this approval, FoundationOne CDx is now approved as a CDx for current and future therapies that are approved under these group indications.2

Additional Notes

* Data on file, Foundation Medicine, Inc, 2021

1 U.S. Food & Drug Administration. List of Cleared or Approved Companion Diagnostic Devices. Content current as of December 9, 2021. Accessed December 9, 2021. www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools

2 FoundationOne CDx reports will include this indication by January 20th, 2022

Important Safety Information

Select

FoundationOne CDx

FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com